GLP-1 Comparison: All Options Available in Nigeria

The GLP-1 medication landscape has expanded rapidly over the past few years. What was once a single option has become a category with distinct medications offering different mechanisms and outcomes. Here's an honest comparison of what's actually available and effective for weight loss in Nigeria.

Semaglutide: The Established Standard

Semaglutide arrived first and has the longest track record for weight loss applications. Originally approved for type 2 diabetes, higher doses were subsequently approved specifically for obesity treatment after clinical trials demonstrated consistent, significant weight reduction.

How it works: Pure GLP-1 receptor agonist. Activates the same receptors as your body's natural GLP-1 hormone but remains active for approximately one week rather than minutes.

Clinical results: Published clinical research showed clinically meaningful weight loss over 68 weeks. About one-third of participants achieved substantial results.

Administration: Weekly subcutaneous injection. Available in pen format for easy self-administration.

Titration schedule: Starts at 0.25mg weekly, increasing monthly through 0.5mg, 1mg, 1.7mg, to maintenance dose of 2.4mg. Full escalation takes approximately 16-20 weeks.

Side effects: Nausea (most common during dose increases), constipation, diarrhea, decreased appetite. Most gastrointestinal effects diminish over time.

Tirzepatide: The Dual-Action Contender

Tirzepatide distinguishes itself by targeting two receptor systems instead of one. This dual mechanism has produced notably higher efficacy numbers in clinical trials, though individual responses still vary.

How it works: Activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP affects fat tissue metabolism and has additional appetite-regulating properties beyond GLP-1 alone.

Clinical results: Published clinical studies demonstrated significant weight loss. More than half of participants achieved substantial results. These numbers approach what's typically seen with bariatric surgery.

Administration: Weekly subcutaneous injection. Similar pen delivery system to semaglutide.

Titration schedule: Starts at 2.5mg weekly, increasing through 5mg, 7.5mg, 10mg, 12.5mg, to maximum of 15mg. Full escalation takes approximately 20 weeks.

Side effects: Similar gastrointestinal profile to semaglutide. Some studies suggest slightly more GI symptoms during escalation, though this varies by individual.

Retatrutide: The Triple-Action Newcomer

Retatrutide represents the newest approach, adding glucagon receptor activation to the GLP-1 and GIP mechanisms. Early trial data has generated significant interest, though the medication is still in late-stage development.

How it works: Triple agonist targeting GLP-1, GIP, and glucagon receptors. Glucagon activation may enhance fat burning and metabolic rate beyond what dual agonists achieve.

Clinical results: Phase 2 trials showed average weight loss of 24% at the highest dose over 48 weeks. Some participants lost more than 30% of their body weight.

Administration: Weekly subcutaneous injection. Delivery mechanism similar to existing medications.

Availability: Not yet widely available. Phase 3 trials ongoing. Regulatory approval expected within the next 1-2 years in major markets.

Head-to-Head: Key Differences

Which Should You Choose?

The "best" medication depends entirely on your individual circumstances. Higher efficacy numbers don't automatically mean better outcomes for every person.

Consider semaglutide if: You want the most established medication with the longest safety track record. You're looking for significant but not necessarily maximum weight loss. You've had good responses to other GLP-1 medications in the past.

Consider tirzepatide if: You have substantial weight to lose and want the strongest available option. You have insulin resistance or prediabetes alongside obesity. Previous GLP-1 monotherapy provided inadequate results.

General guidance: Many healthcare providers suggest starting with semaglutide. If results plateau or are insufficient after reaching maintenance dose, switching to tirzepatide becomes an option. This approach balances efficacy with established safety data.

Nigeria-Specific Considerations

Supply chain reliability matters more than medication choice in some ways. Both semaglutide and tirzepatide require proper cold storage. In Nigeria's climate, verifying that your supplier maintains appropriate refrigeration from import to delivery is crucial.

Compounded versions of both medications are available and can offer accessibility advantages. These are prepared by licensed compounding pharmacies. Quality varies by supplier, making source verification essential.

Medical supervision matters regardless of which medication you choose. Proper screening, appropriate titration, and monitoring for side effects significantly improve outcomes and safety. Avoid providers who simply sell medication without any assessment of your health status.

The Bottom Line

Both semaglutide and tirzepatide are effective for weight loss. Tirzepatide generally produces more weight loss on average, but semaglutide has more long-term safety data. Neither is universally "better" because individual responses vary substantially.

What matters most is choosing a reliable source, following proper titration protocols, and maintaining realistic expectations about the timeline and effort involved. These medications make weight loss significantly easier, but they're not instant solutions.